REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters

Cited by (524)

Items 401–500 of 524

1. Treatment of COVID-19 by monoclonal antibodies and the traditional Chinese medicine
   Yuyan Ling, Yuxuan Dong, Qirui Li, Doudou Huang, Zhihui Li, Meijuan Chen · 2022 · Medicine in Novel Technology and Devices
2. An ACE2-IgG4 Fc Fusion Protein Demonstrates Strong Binding to All Tested SARS-CoV-2 Variants and Reduced Lung Inflammation in Animal Models of SARS-CoV-2 and Influenza
   Emmanuel Y. Mérigeon, Dong Yang, Elizabeth A. Ihms, Leda Bassit, Elizabeth Ann Fitzpatrick, Colleen Beth Jonsson, Raymond F. Schinazi, David S. Block, Henrik Steen Olsen · 2022 · Pathogens and Immunity
3. Isolation and Characterization of Neutralizing Monoclonal Antibodies from a Large Panel of Murine Antibodies against RBD of the SARS-CoV-2 Spike Protein
   Emanuela D’Acunto, Alessia Muzi, Silvia Marchese, Lorena Donnici, Valerio Chiarini, Federica Bucci, Emiliano Pavoni, Fabiana Fosca Ferrara, Manuela Cappelletti, Roberto Arriga et al. · 2024 · Antibodies
4. No evidence for enhanced disease with human polyclonal SARS-CoV-2 antibody in the ferret model
   Douglas S. Reed, Anita K. McElroy, Dominique J. Barbeau, Cynthia M. McMillen, N. L. Tilston-Lunel, Sham Nambulli, Emily Cottle, Theron C. Gilliland, Hasala Rannulu, Jeneveve D. Lundy et al. · 2024 · PLoS ONE
5. Insights into the virologic and immunologic features of SARS-COV-2
   Ceylan Polat, Koray Ergünay · 2021 · World Journal of Clinical Cases
6. Pharmacokinetic profiles of a SARS‐COV‐2 neutralizing antibody BD‐604 in cynomolgus monkeys
   Feng Gao, Xu Zhang · 2021 · Drug Testing and Analysis
7. 'One Year Later' - SARS-CoV-2-Specific Immunity in Mild Cases of COVID-19
   Pablo García-Valtanen, Christopher M. Hope, Makutiro Ghislain Masavuli, Arthur Eng Lip Yeow, Harikrishnan Balachandran, Zelalem Addis Mekonnen, Zahraa Al-Delfi, Arunasingam Abayasingam, David Agapiou, Jason Gummow et al. · 2021 · SSRN Electronic Journal
8. Cornering an Ever-Evolving Coronavirus: TATX-03, a fully human synergistic multi-antibody cocktail targeting the SARS-CoV-2 Spike Protein with in vivo efficacy
   Ilse Roodink, Maartje van Erp, Andra Li, Sheila Potter, Sander M. J. van Duijnhoven, Arthur J. Kuipers, Bert Kazemier, Ellen W. van Geffen, Wieger Hemrika, Bob Berkeveld et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
9. Early post-infection treatment of SARS-CoV-2 infected macaques with human convalescent plasma with high neutralizing activity reduces lung inflammation
   K. V. van Rompay, K. Olstad, R. Sammak, Joseph C. Dutra, Jennifer K. Watanabe, J. Usachenko, Ramya Immareddy, Jamin W. Roh, A. Verma, Yashavanth Shaan Lakshmanappa et al. · 2021 · bioRxiv
10. Cross-reactive single-domain antibodies to hemagglutinin stem region protect mice from group 1 influenza A virus infection
    Daria V. Voronina, Банделюк Алина Сергеевна, Alina Sh. Dzharullaeva, Olga D. Popova, Vladislav Y. Kan, Ilias B. Esmagambetov, Irina A. Favorskaya, Dmitry V. Shcheblyakov, Boris Savelyevich Naroditskiy, Gintsburg Al · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
11. Preferential apical infection and spread of human metapneumovirus highlights the importance of inhaled delivery of neutralizing monoclonal antibody to treat established infections
    Karthik Tiruthani, Madison P. Card, Whitney Wolf, Limei Shen, Alison Schaefer, Marshall Fritz, Kenichi Okuda, Jack R. Harkema, Jarrod J. Mousa, Raymond John Pickles et al. · 2025 · Proceedings of the National Academy of Sciences
12. The use of neutralizing monoclonal antibodies against SARS-CoV-2 in hemodialysis patients
    E.V. Volodina, Nadiya F. Frolova, Mariana A. Lysenko, Irina G. Kim, A.I. Ushakova, Виноградов Владимир Евгеньевич, S.S. Usatiuk, A.M. Nikitina, Маркина Ульяна Алексеевна, V.I. Chervinko et al. · 2022 · Infectious diseases News Opinions Training
13. Treatment for Covid-19 with SARS-CoV-2 neutralizing antibody BRII-196(Ambavirumab) plus BRII-198(Lomisivir): a retrospective cohort study
    Qin Yalan, Hao Lingfang, Liu Xisong, Run Liang, Zhang Junjing, Zhang’ An · 2024 · BMC Pharmacology and Toxicology
14. Design and antiviral assessment of a panel of fusion proteins targeting human papillomavirus type 16
    Chongzhi Bai, Ruoyu Wang, Qian Yang, Jianqing Hao, Qiming Zhong, Ruiwen Fan, Pengcheng Han · 2024 · PLoS ONE
15. Human Source Severe Acute Respiratory Syndrome Coronavirus 2 Aerosol Transmission to Remote Sentinel Hamsters
    Chad J. Roy, Michael R. Barer, Veronica Ueckermann, Brandon J. Beddingfield, David Cordier, Petrus Bernard Fourie, Richard L. Vincent, Sego Dibobo, Toby VanReenen, Paul Arthur Jensen et al. · 2025 · Open Forum Infectious Diseases
16. Participación de las respuestas inmunes en el control de la COVID-19
    Cristina Pérez · 2022 · Revista Ecuatoriana de Medicina y Ciencias Biológicas
17. Pharmacokinetic and Pharmacodynamic Effects of Polyclonal Antibodies against SARS-CoV2 in Mice
    Aruni Jha, Melanie Doyle‐Eisele, David Revelli, Trevor J. Carnelley, Douglas Barker, Shantha Kodihalli · 2022 · Viruses
18. Lack of efficacy of mono‐mode of action therapeutics in COVID‐19 therapy ‐ How the lack of predictive power of preclinical cell and animal studies leads developments astray
    Annekathrin Haberland, Johannes Müller · 2021 · Chemical Biology & Drug Design
19. Complex Pathophysiological Mechanisms and the Propose of the Three-Dimensional Schedule For Future COVID-19 Treatment
    Yonggang Zhou, Xiuxiu Xu, Haiming Wei · 2021 · Frontiers in Immunology
20. Development and characterization of SARS-CoV-2 variant-neutralizing monoclonal antibodies
    Hongyu Qiu, Xin-Yong Yuan, Teresa M. Cabral, Kathy Manguiat, Alyssia Robinson, Heidi Wood, Chris Grant, Peter McQueen, Garrett Westmacott, Daniel R. Beniac et al. · 2021 · Antiviral Research
21. The impact of COVID-19 monoclonal antibodies on clinical outcomes: A retrospective cohort study
    Arielle R. Nagler, Leora Idit Horwitz, Simon Jones, Christopher Michael Petrilli, Eduardo Iturrate, Jennifer Lighter, Michael Phillips, Brian P. Bosworth, Bruce Polsky, Frank Volpicelli et al. · 2022 · American Journal of Health-System Pharmacy
22. Technologies for Making New Vaccines
    Simone Pecetta, Sohail Ahmed, Ronald W. Ellis, Rino Rappuoli · 2023 · Elsevier eBooks
23. Genetic barrier to resistance: a critical parameter for efficacy of neutralizing monoclonal antibodies against SARS-CoV-2 in a nonhuman primate model
    Christiane Stahl‐Hennig, Antonia Sophia Peter, Arne Cordsmeier, Nicole Stolte, Ramona Vestweber, Eileen Socher, Samuel Alberto Mérida Ruíz, Ulrike Sauermann, Martina Bleyer, Kirsten Fraedrich et al. · 2024 · Journal of Virology
24. Insights into biological therapeutic strategies for COVID-19
    Xiaolong Tian, Cheng Li, Yan-Ling Wu, T. Ying · 2021 · Fundamental Research
25. Evidence of the Clinical Efficacy of Antiviral Agents against SARS-CoV-2
    Angelique Welman, Kim Outhoff · 2021 · International Journal Of Pharmaceutical Research And Allied Sciences
26. Single dose immunization with a COVID-19 DNA vaccine encoding a chimeric homodimeric protein targeting receptor binding domain (RBD) to antigen-presenting cells induces rapid, strong and long-lasting neutralizing IgG, Th1 dominated CD4 + T cells and strong CD8 + T cell responses in mice
    Gunnstein Norheim, Elisabeth Stubsrud, Lise Madelene Skullerud, Branislava Stankovic, Stalin Chellappa, Louise Bjerkan, Katarzyna Kuczkowska, Elisabeth Müller, Monika Sekelja, Agnete Brunsvik Fredriksen · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
27. Host cell membrane capture by the SARS CoV-2 spike protein fusion intermediate
    Rui Su, Jin Zeng, Ben O’Shaughnessy · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
28. Anticuerpos Anti SARS-CoV-2, Post-vacunación en Cochabamba, Bolivia
    Jhonny Limachi-Choque, Aleida Verduguez-Orellana · 2022 · Gaceta Médica Boliviana
29. Evaluating the Clinical Efficacy of Antiviral Treatments for SARS-CoV-2
    Angelique Welman, Kim Outhoff · 2021 · Pharmaceutical Sciences and Drug Design
30. Modeling Virus-Associated Central Nervous System Disease in Non-Human Primates
    Krystal J. Vail, Brittany N Macha, L. Hellmers, Tracy Fischer · 2025 · International Journal of Molecular Sciences
31. Engineering virus-like particles for safe and versatile modeling of SARS-CoV-2 host interaction and immune escape
    Liang Ma, Lin Yuan, Siyu Ma, Kai Chen, Yihan Lin · 2025 · Communications Biology
32. RETRACTED: Severe acute respiratory syndrome coronavirus 2–mediated dysregulation of drug processing genes is dependent on pathogenic variants, target site of infection, age, and sex
    Chukwunonso K. Nwabufo · 2025 · Drug Metabolism and Disposition · Retracted
33. Development of a potent protective felinized chimeric antibody C8A8 targeting feline and canine parvovirus
    Yajie Sun, Chengqi Zhang, Jiajia Liu, Dingrui Guo, Shuangshuang Li, Liwen Xu, Bo Hu, Haifeng Zeng, Yawen Liu, Jianhai Fu et al. · 2025 · Veterinary Microbiology
34. B Cell Receptor’s function in virus entry: Anti-SARS-CoV-2 B cell receptors can mediate viral entry in an ACE2-independent mechanism
    Rene Larios, Md Belal Hossain, Rebecca Brown, Arjit Vijey Jeyachandran, Angel Elma I. Abu, Anne K. Zaiss, Christina M. Ramirez, Masakazu Kamata, Steve Cole, Ting-Ting Wu et al. · 2026 · PLoS Pathogens
35. A delayed dynamical model for COVID-19 therapy with defective interfering particles and artificial antibodies
    Yanfei Zhao, Yepeng Xing · 2021 · Discrete and Continuous Dynamical Systems - B
36. Databases, DrugBank, and virtual screening platforms for therapeutic development
    Sushil Kumar Middha, Anjlina David, Shoumi Haldar, Hankhray Boro, Prachurjya Panda, Nikitha Bajare, Ligi Milesh, VR Devaraj, Talambedu Usha · 2022 · Elsevier eBooks
37. Host Cell Entry and Neutralization Sensitivity of SARS-CoV-2 Lineages B.1.620 and R.1
    Anzhalika Sidarovich, Nadine Krüger, Cheila Rocha, Luise Graichen, Amy Madeleine Kempf, Inga Nehlmeier, Martin Lier, Anne Cossmann, Metodi V. Stankov, Sebastian R. Schulz et al. · 2022 · Viruses
38. Preclinical studies of antiviral activity of the RPH-137 fusion protein and molnupiravir against COVID-19
    E. Shipaeva, O. Filon, A. Zintchenko, G. Shipunov, A. Dmitrieva, M. Lemak, S. Grishin, E. I. Trofimets, K. Kryshen, L. Kozlovskaya et al. · 2022 · Biological Products. Prevention, Diagnosis, Treatment
39. Novel neutralizing SARS-CoV-2-specific mAbs offer detection of RBD linear epitopes
    Seyed Mostafa Mostafavi Zadeh, Ali Ahmad Bayat, Hosein Shahsavarani, Feridoun Karimi‐Busheri, Jafar Kiani, Roya Ghods, Zahra Madjd · 2024 · Virology Journal
40. The Use of Animal Models for Antiviral Therapeutics Development: Opportunities and Challenges
    Islam Abbadi, Mustapha Lkhider, Ahd Ouladlahsen, Haya Altawalah, Ali Ahmed Rabaan, Fadila Guessous, Sayeh Ezzikouri · 2024 · Livestock diseases and management
41. Development of Human Monoclonal Antibodies With Broad Reactivity for Rabies Postexposure Prophylaxis
    Meng Wu, Xinyu Peng, Weidi Xu, Han Zhang, Lian Fang, Xueqin Liu, Faming Miao, Quan Liu, Shijiang Mi, Yuewen Xiao et al. · 2024 · Journal of Medical Virology
42. Human Pluripotent Stem Cell–Derived Cardiomyocytes for COVID-19 Cardiovascular Complications: A Versatile In Vitro Model for Studying Acute and Chronic SARS-CoV-2 Infection
    Carmen Lopez-Munoz, Noah Jackson Bowers, Silvia Marchianò · 2025 · Current Treatment Options in Cardiovascular Medicine
43. Going back in time for an antibody to fight COVID-19
    Gary R. Whittaker, Susan Daniel · 2020 · Nature
44. Vaccines and Treatment of Coronavirus Disease 2019
    Pyoeng Gyun Choe · 2020 · Korean Journal of Medicine
45. Evaluating And Referring Patients For Outpatient Monoclonal Antibody Therapy For Coronavirus (COVID-19) In The Emergency Department
    Abdul Aleem, Olubunmi Olarewaju, Alexander Pozun · 2021 · StatPearls
46. SARS-Cov-2 Coronavirus Infection in Wild Animals
    Alex Lécu · 2023 · Elsevier eBooks
47. IMPACT OF DIFFERENT DRUGS OR MEDICATION ON COVID-19: A REVIEW
    Ankita Harishchandra Tripathi, Ibhya Singh, Priya Pandey, Pooja Chaurasia, Swati S. Jain, Sristi Raj, Akanksha Pandey, T B Singh · 2023 · Journal of Biological and Scientific Opinion
48. The Efficacy of Recombinant Drugs in COVID-19 Treatment
    Mostafa Norizadeh · 2023 · Advances in Pharmacology & Clinical Trials
49. Current knowledge on the treatment of COVID-19
    Mahendra Singh Pal, Kirubel Paulos Gutama · 2022 · MOJ Biology and Medicine
50. MTX-COVAB, a human-derived antibody with potent neutralizing activity against SARS-CoV-2 infection in vitro and in a hamster model of COVID-19
    Simone Schmitt, Marcel Weber, Matthias Hillenbrand, Jemima Seidenberg, Andreas Zingg, Catherine L. Townsend, Barbara Eicher, Justina Rutkauskaite, Peggy Riese, Carlos A. Guzmán et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
51. Preclinical Efficacy of IMM-BCP-01, a Highly Active Patient-Derived Anti-SARS-CoV-2 Antibody Cocktail
    Pavel A. Nikitin, Jillian M. DiMuzio, John P. Dowling, Nirja B. Patel, Jamie L. Bingaman, Baron C. Heimbach, Noeleya Henriquez, Chris Nicolescu, Antonio M Polley, Eden L. Sikorski et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
52. Targeting SARS-CoV-2 infection through CAR-T like bispecific T cell engagers incorporating ACE2
    Mikail Dogan, Lina Kozhaya, Lindsey Placek, Fatih Karabacak, Mesut Yiğit, Derya Unutmaz · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
53. Converting non-neutralizing SARS-CoV-2 antibodies targeting conserved epitopes into broad-spectrum inhibitors through receptor blockade
    Payton A. B. Weidenbacher, Eric Waltari, Izumi de los Rios Kobara, Benjamin N. Bell, John E. Pak, Peter S. Kim · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
54. Accelerating Drug Discovery and Development
    Xianhai Huang, David Yu‐Kai Chen, Wayne Tang · 2022
55. The effects of ethyl lauroyl arginine hydrochloride( ELAH) in nasal spray on SARS-C0V-2
    Abdul Gaffar, Harshad R. Thacore, Seiyoung Yun, Agnes Chemine, Maria G. Ferrari, Ranagit Pal, Lauren Wattay, Marnie L. Peterson · 2022 · Research Square
56. Computational Analysis of Antibody Binding Mechanisms to the Omicron RBD of SARS-CoV-2 Spike Protein: Identification of Epitopes and Hotspots for Developing Effective Therapeutic Strategies
    Mohammed Alshahrani · 2023 · Chapman University Digital Commons (Chapman University)
57. PCR data accurately predict infectious virus: a characterization of SARS-CoV-2 in non-human primates
    Celine E. Snedden, J. Lloyd-Smith · 2023 · bioRxiv
58. Cross-Neutralizing Monoclonal Antibodies with Broad Activity Against Human and Bat-Derived SARS-Related Coronaviruses
    Martin Mayora Neto, Kelly da Costa, Diego M. Cantoni, Mariliza Derveni, Edward Wright, Heinz Hoschuetzky, Franz Kaufmann, Petra Schuessler, Nigel James Temperton · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
59. A SARS-CoV-2 antiviral therapy score card
    Robert W. Shafer · 2020 · Global Health & Medicine
60. SARS-CoV-2 B cell receptor signatures in at-risk populations
    Andrew I. Flyak · 2020 · Journal of Clinical Investigation
61. Long-term persistence of neutralizing memory B cells in SARS-CoV-2
    Rowena Anne Bull, Arunasingam Abayasingam, Harikrishnan Balachandran, David Agapiou, Chaturaka Rodrigo, Elizabeth Keoshkerian, Hui Li, Nicholas A. Brasher, Daniel Christ, Romain Rouet et al. · 2020 · Research Square
62. Covid-19 Treatment: A Narrative Review of the Research and Evidence Thus Far
    Rahim SM Zubair, Connolly Derek L, Arvind Rajasekaran, Sharma Vinoda · 2020 · Scholarly Journal of Emergency Medicine and Critical Care
63. Assessment of anti SARS-CoV-2 antibodies present in convalescent plasma donors aimed at being used in COVID-19 treatment
    Spînu Constantin, Svetlana CEBOTARI, Octavian Sajin, I Spînu, Ala Donos, Volneanschi Ana, Igor Gostev, Iurie DOPIRA · 2021 · One Health & Risk Management
64. Evaluation of efficacy of the amino acid-peptide complex administered intragastrically to golden hamsters experimentally infected with SARS-CoV-2
    Denis Sergeevich Laptev, G. A. Protasova, Sergey Gervasievich Petunov, AS Radilov, SV Chepur, AS Gogolevskiy, VA Myasnikov, MA Tyunin, AV Smirnova · 2021 · Medicine of Extreme Situations
65. Long-Term Persistence and Relevant Therapeutic Impact of High-Titer Viral-Neutralizing Antibody in a Convalescent COVID-19 Plasma Super-Donor: A Case Report
    Mafalda De Rienzo, Maria Laura Foddai, Laura Conti, Chiara Mandoj, Stefano Iaboni, Ilenia Saladini, Concetta Castilletti, Giulia Matusali, Davide Roberto Donno, Luisa Marchioni et al. · 2021 · Frontiers in Immunology
66. Role of syrian hamsters and nonhuman primates in covid-19 research
    Deepak Y. Patil, Sreelekshmy Mohandas, Pragya Dhruv Yadav · 2021 · Indian Journal of Comparative Microbiology Immunology and Infectious Diseases
67. A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in rhesus macaques
    Ronald R. Cobb, Joseph P. Nkolola, P. Gilchuk, A. Chandrashekar, R. V. House, Christopher G. Earnhart, N. Dorsey, Svetlana A. Hopkins, Doris M. Snow, Rita E. Chen et al. · 2021 · bioRxiv
68. Casirivimab and imdevimab as investigational monoclonal antibodies for COVID-19 patients – review of the literature
    Gabriela Ręka, Angelika Pawlak, Piotr Artur Machowiec, Marcela Maksymowicz, Halina Piecewicz‐Szczęsna · 2021 · Current Issues in Pharmacy and Medical Sciences
69. Directed Evolution of Antibodies Against Complex Targets
    Alec A. Desai · 2021 · Deep Blue (University of Michigan)
70. The cellular characterisation of SARS-CoV-2 spike protein in virus-infected cells using Receptor Binding Domain-binding specific human monoclonal antibodies
    Conrad En-Zuo Chan, Ching-Ging Ng, Angeline Pei-Chew Lim, Shirley G. K. Seah, De Hoe Chye, Steven K. K. Wong, Jie-Hui Lim, Vanessa Zi-Yun Lim, Soak-Kuan Lai, Pui-San Wong et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
71. SARS-CoV-2 on the move: Reviewing Innate vs Acquired for Covid-19
    S. Banerjee · 2021
72. Robust and durable prophylactic protection conferred by RNA interference in preclinical models of SARS-CoV-2
    Yesseinia Angleró-Rodríguez, Florian A. Lempp, James McIninch, Mark K. Schlegel, Christopher R. Brown, Donald J. Foster, Adam B. Castoreno, Tuyen M Nguyen, Megha P. Subramanian, Martin Montiel-Ruiz et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
73. Intranasal inhibitor broadly blocks SARS-CoV-2 including recent highly immunoevasive Omicron subvariants
    Anna R. Mäkelä, Hasan Uğurlu, Liina Hannula, Ravi Kant, Petja Salminen, Riku Fagerlund, Sanna Mäki, Anu Haveri, Tomas M. Strandin, Lauri Kareinen et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
74. Targeting SARS-CoV-2 Infection Through CAR-T Like Bispecific T Cell Engagers Incorporating ACE2
    Mikail Dogan, Lina Kozhaya, Lindsey Placek, Fatih Karabacak, Mesut Yiğit, Derya Unutmaz · 2022 · SSRN Electronic Journal
75. Biotechnology strategies for the development of novel therapeutics and vaccines against the novel COVID-19 pandemic
    Kenneth H. Lundstrom · 2022 · Elsevier eBooks
76. Special focus on SARS-CoV-2 and other zoonotic respiratory coronaviruses in animal models
    H. Adissu, D. Meyerholz, Amanda J. Martinot, J. Ward · 2022 · Veterinary Pathology-Supplement
77. Fc-modified SARS-CoV-2 neutralizing antibodies with therapeutic effects in two animal models
    Masaru Takeshita, Hidehiro Fukuyama, Katsuhiko Kamada, Takehisa Matsumoto, Chieko Makino‐Okamura, Tomomi Uchikubo‐Kamo, Yuri Tomabechi, Kazuharu Hanada, Saya Moriyama, Yoshimasa Takahashi et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
78. The use of neutralizing monoclonal antibody in patients with COVID-19: a systematic review and meta-analysis
    Suzana Érico Tanni, Diane Rezende Batista, Hélio Arthur Bacha, Alexandre Naime Barbosa, Wanderley Marques Bernardo · 2022 · Revista da Associação Médica Brasileira
79. Long-term passaging of replication competent pseudo-typed SARS-CoV-2 reveals the antiviral breadth of monoclonal and bispecific antibody cocktails
    Han-Hui Ma, Huifang Zong, Jun-jun Liu, Ya-Li Yue, Yong Ke, Yu-Jou Liao, Hao-Neng Tang, Lei Wang, Shusheng Wang, Yunsheng Yuan et al. · 2022 · bioRxiv
80. ЗАСТОСУВАННЯ ГЕННОІНЖЕНЕРНИХ ЗАСОБІВ У ЛІКУВАННІ ХВОРИХ НА COVID-19
    В. Д. Москалюк, B.V. Syrota · 2022 · Інфекційні хвороби
81. Deep mutational scanning to predict antibody escape in SARS-CoV-2 Omicron subvariants
    Mellissa C. Alcantara, Yusuke Higuchi, Yuhei Kirita, Satoaki Matoba, Atsushi Hoshino · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
82. Experience in the use of neutralizing monoclonal antibodies in kidney transplant recipients with COVID-19
    I. G. Kim, Лысенко Марьяна Анатольевна, Nadiya F. Frolova, L. Yu. Аrtyukhina, Т.А. Buruleva, A. M. Nikitina, Виноградов Владимир Евгеньевич, E.V. Volodina, V.I. Chervinko, Evgeniy V. Kryukov et al. · 2023 · Russian Journal of Transplantology and Artificial Organs
83. Casirivimab/Imdevimab: Possible Candidate for COVID-19 Treatment in Pets: Traditional Review
    Fatma Ender, Serkan Sayıner, Sevgi Gençosman, Deniz Ceylanlı, Güzin Özkurt, Nurettin Abacıoğlu, Ahmet Özer Şehirli · 2023 · Turkiye Klinikleri Journal of Veterinary Sciences
84. Isolation and characterization of neutralizing monoclonal antibodies from a large panel of murine antibodies against RBD of the SARS-CoV-2 Spike protein
    Emanuela D’Acunto, Alessia Muzi, Silvia Marchese, Lorena Donnici, Valerio Chiarini, Federica Bucci, Emiliano Pavoni, Fabiana Fosca Ferrara, Manuela Cappelletti, Roberto Arriga et al. · 2023 · Research Square
85. No evidence for enhanced disease with polyclonal SARS-CoV-2 antibody in the ferret model
    D. Reed, Anita K. McElroy, Dominique J. Barbeau, Cynthia M. McMillen, N. L. Tilston-Lunel, Sham Nambulli, Emily Cottle, Theron C. Gilliland, Hasala Rannulu, Jeneveve D. Lundy et al. · 2023 · bioRxiv
86. Development of plant-produced subunit vaccine and therapeutic protein for COVID-19
    Konlavat Siriwattananon · 2021
87. RBD-specific single-chain antibody protects against acute lung injury in mice
    Shanshan Peng, Syed Husnain Raza Shah, Shengsheng Mei, Eu Gene Vong, Yisheng Sun, Jin-biao Zhan · 2023 · International Immunopharmacology
88. An Initial Experience with Antibody Cocktail CASIRIVIMAB and IMDEVIMAB in a Center of Excellence
    P Amal Johnson, T. Suresh Babu, R Narasimhan · 2021 · Journal of Association of Pulmonologist of Tamil Nadu
89. A glycoengineered therapeutic anti-HBV antibody that allows increased HBsAg immunoclearance improves HBV suppression in vivo
    Min You, Fentian Chen, Chao Yu, Yuanzhi Chen, Yue Wang, Xue Liu, Xueran Guo, Bing Nan Zhou, Xin Wang, Boya Zhang et al. · 2023 · Frontiers in Pharmacology
90. APPLICATION OF GENE ENGINEERING IN THE TREATMENT OF PATIENTS WITH COVID-19
    В.Д. Москалюк, Iryna V. Balaniuk, С.Р. Меленко, Yu. O. Randiuk · 2024 · Medical Science of Ukraine (MSU)
91. Recombinant ACE2 - Opportunities and Challenges in COVID-19 Treatment
    Mandeep Kaur, Rahul Sandhu, Akriti Aggarwal · 2024 · Infectious Disorders - Drug Targets
92. Evidence that the SARS-CoV-2 S protein undergoes a conformational change at the Golgi Complex that leads to the formation of virus neutralising antibody binding epitopes in the S1 protein subunit.
    Richard Joseph Sugrue, Boon Huan Tan, Soak Kuan Lai, Conrad En-Zuo Chan, Yanjun Wu · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
93. Drugs actively being investigated for use in COVID-19
    Ruiqi Zhang, Ivan Fan‐Ngai Hung · 2024 · Elsevier eBooks
94. The PERSPECTIVES OF BIOTECHNOLOGICAL DEVELOPMENT IN KAZAKHSTAN IN TERMS OF MONOCLONAL AND OTHER RECOMBINANT ANTIBODIES AND VACCINES AGAINST SARS-COV2
    S. Khaidarov, E. R. Tulman · 2024 · Experimental biology
95. Evidence that the SARS-CoV-2 S protein undergoes a conformational change at the Golgi complex that leads to the formation of virus neutralising antibody binding epitopes in the S1 protein subunit
    Yanjun Wu, Soak Kuan Lai, Conrad En-Zuo Chan, Boon Huan Tan, Richard Joseph Sugrue · 2024 · Virology
96. Multiplex Microscopy Assay for Assessment of Therapeutic and Serum Antibodies against Emerging Pathogens
    Nuno Sartingen, Vanessa S. Stürmer, Matthias Kaltenböck, Thorsten G. Müller, Paul Schnitzler, Anna Kreshuk, Hans‐Georg Kräusslich, Uta Merle, Frauke Muecksch, Bárbara Müller et al. · 2024 · Viruses
97. Analysis of the course and outcomes of COVID-19 at different stages of the pandemic in hemodialysis patients
    Nadiya F. Frolova, Irina G. Kim, V.I. Chervinko, E.V. Volodina, M.L. Zubkin · 2024 · Nephrology and Dialysis
98. Neutralizing antibodies against SARS-CoV-2
    Saya Moriyama · 2023 · Uirusu
99. Revisiting the COVID-19 Pandemic: A Comparative Analysis between Traditional and Synthetic Modes of Treatment with the Aid of In-silico Methods
    Priyam Jyoti Das, Durgaprasad Kemisetti, Sherine Ahmed, Faruk Alam · 2024 · Coronaviruses
100. Long COVID symptoms 6 months after acute infection among people living with HIV and people not living with HIV
     Qin Li, Yijie Ma, Peng He, Dongqiong Chen, Tingrui Zhang, Xiaoying Wang, Ying Xu, Peiming Li, Weibo Wen, Zefeng Wang · 2024 · Frontiers in Immunology